IRF2 regulates cellular survival and Lenvatinib-sensitivity of hepatocellular carcinoma (HCC) through regulating β-catenin

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide. Lenvatinib oral chemotherapy is approved as a first-line treatment of patients with unresectable HCC. The efficacy and therapeutic duration of lenvatinib are limited by drug resistance, and the mechanism is...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Transl Oncol
Hlavní autoři: Guo, Yarong, Xu, Jun, Du, Qiang, Yan, Yihe, Geller, David A.
Médium: Artigo
Jazyk:Inglês
Vydáno: Neoplasia Press 2021
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7988337/
https://ncbi.nlm.nih.gov/pubmed/33735820
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.tranon.2021.101059
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky